Related Experiment Video
Updated: Jul 12, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Constitutive DUSP2 expression enhances lymphoid cell proliferation by activating CDK1 and promotes lymphomagenesis
Yu Qian1, Jutatip Panaampon1, Bjoern Chapuy2
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Insights
Dual-specificity phosphatase 2 (DUSP2) unexpectedly drives lymphoid malignancies by promoting cell cycle progression. Inhibiting DUSP2 may offer a novel therapeutic strategy for these cancers.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- Dual-specificity phosphatase 2 (DUSP2) is a nuclear phosphatase primarily found in immune cells.
- Its expression increases with immune cell stimulation and is linked to differentiation and function.
- The role of DUSP2 in immune cell proliferation and hematologic cancers remains unclear.
Purpose of the Study:
- To investigate the role of DUSP2 in immune cell proliferation and hematologic malignancies.
- To elucidate the underlying mechanisms by which DUSP2 influences cell cycle progression and cancer development.
Main Methods:
- Analysis of DUSP2 expression in human hematologic malignancies.
- Gene silencing of DUSP2 in lymphoma cell lines.
- Transgenic mouse models with altered DUSP2 expression.
- Biochemical assays to determine DUSP2's interaction with cell cycle regulators.
Main Results:
- DUSP2 is highly expressed in various human hematologic malignancies, including B-cell and T-cell lymphomas.
- Reducing DUSP2 levels in lymphoma cells inhibits their growth and viability.
- Elevated DUSP2 expression in mice enhances B-cell and T-cell proliferation and promotes malignant transformation.
- DUSP2 activates CDK1 by recruiting CDC25 phosphatases, independent of its own catalytic activity, thus promoting cell cycle progression.
Conclusions:
- DUSP2 plays an unexpected oncogenic role in lymphoid malignancies.
- A structural motif in DUSP2, rather than its phosphatase activity, mediates cell cycle activation.
- DUSP2 represents a potential therapeutic target for treating hematologic cancers.
Abstract:
DUSP2 is known as a nuclear dual-specificity phosphatase, highly restricted to immune cells. Its expression is induced by antigenic and mitogenic stimuli and has been implicated in immune cell differentiation and functions. However, its role in immune cell mitotic proliferation and hematologic malignancies has not been rigorously examined. Here, we show DUSP2 is highly expressed in human B-cell, T cell, and other hematologic malignancies. Ablating DUSP2 expression in lymphoma cell lines decreases growth and viability. In mice, transgenic Dusp2 expression promotes B-cell and T cell proliferation, and malignant transformation. Mechanistically, DUSP2 promotes cell cycle progression by activating CDK1 through dephosphorylation at inhibitory Tyr15 and Thr14, which is mediated not by its own phosphatase activity, but instead by a structural motif that recruits CDC25 phosphatases. This work reveals an unexpected oncogenic role for DUSP2 in lymphoid malignancies and the function of a structural motif, which represents an appealing target site for therapeutic intervention.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Inhibition of Cdk Activity
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Mitogens and the Cell Cycle
Positive Regulator Molecules
S-Cdk Initiates DNA Replication
Two states at the origin of replication
In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of replication.

